| Host: |
Rabbit |
| Applications: |
WB |
| Reactivity: |
Human |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
Rabbit monoclonal antibody anti-Neuropilin-1 (22-644) is suitable for use in Western Blot research applications. |
| Clonality: |
Monoclonal |
| Clone ID: |
S4753RM |
| Conjugation: |
Unconjugated |
| Isotype: |
IgG |
| Formulation: |
PBS with 0.05% Proclin300, 0.05% BSA, 50% Glycerol, pH7.3. |
| Purification: |
Affinity purification |
| Dilution Range: |
WB 1:1000-1:5000 |
| Storage Instruction: |
Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
| Gene Symbol: |
NRP1 |
| Gene ID: |
8829 |
| Uniprot ID: |
NRP1_HUMAN |
| Immunogen Region: |
22-644 |
| Immunogen: |
Recombinant fusion protein containing a sequence corresponding to amino acids 22-644 of human Neuropilin-1 (NRP1) (NP_003864.5). |
| Immunogen Sequence: |
FRNDKCGDTIKIESPGYLTS PGYPHSYHPSEKCEWLIQAP DPYQRIMINFNPHFDLEDRD CKYDYVEVFDGENENGHFRG KFCGKIAPPPVVSSGPFLFI KFVSDYETHGAGFSIRYEIF KRGPECSQNYTTPSGVIKSP GFPEKYPNSLECTYIVFVPK MSEIILEFESFDLEPDSNPP GGMFCRYDRLEIWDGFPDVG PHIGRYCGQKTPGRIRSSSG ILSMVFYTDSAIAKEGFSA |
| Tissue Specificity | Isoform 1: The expression of isoforms 1 and 2 does not seem to overlap. Expressed in olfactory epithelium (at protein level). Expressed in fibroblasts (at protein level). Expressed by the blood vessels of different tissues. In the developing embryo it is found predominantly in the nervous system. In adult tissues, it is highly expressed in heart and placenta.moderately in lung, liver, skeletal muscle, kidney and pancreas.and low in adult brain. Expressed in the central nervous system, including olfactory related regions such as the olfactory tubercles and paraolfactory gyri. Isoform 2: The expression of isoforms 1 and 2 does not seem to overlap. Found in liver hepatocytes, kidney distal and proximal tubules. |
| Function | Cell-surface receptor involved in the development of the cardiovascular system, in angiogenesis, in the formation of certain neuronal circuits and in organogenesis outside the nervous system. Mediates the chemorepulsant activity of semaphorins. Recognizes a C-end rule (CendR) motif R/KXXR/K on its ligands which causes cellular internalization and vascular leakage. It binds to semaphorin 3A, the PLGF-2 isoform of PGF, the VEGF165 isoform of VEGFA and VEGFB. Coexpression with KDR results in increased VEGF165 binding to KDR as well as increased chemotaxis. Regulates VEGF-induced angiogenesis. Binding to VEGFA initiates a signaling pathway needed for motor neuron axon guidance and cell body migration, including for the caudal migration of facial motor neurons from rhombomere 4 to rhombomere 6 during embryonic development. Regulates mitochondrial iron transport via interaction with ABCB8/MITOSUR. (Microbial infection) Acts as a host factor for human coronavirus SARS-CoV-2 infection. Recognizes and binds to CendR motif RRAR on SARS-CoV-2 spike protein S1 which enhances SARS-CoV-2 infection. Isoform 2: Binds VEGF-165 and may inhibit its binding to cells. May induce apoptosis by sequestering VEGF-165. May bind as well various members of the semaphorin family. Its expression has an averse effect on blood vessel number and integrity. |
| Protein Name | Neuropilin-1Vascular Endothelial Cell Growth Factor 165 ReceptorCd Antigen Cd304 |
| Database Links | Reactome: R-HSA-194306Reactome: R-HSA-376176Reactome: R-HSA-399954Reactome: R-HSA-399955Reactome: R-HSA-399956Reactome: R-HSA-445144Reactome: R-HSA-447041Reactome: R-HSA-9694614 |
| Cellular Localisation | Isoform 2: SecretedMitochondrion MembraneSingle-Pass Type I Membrane ProteinCell MembraneCytoplasm |
| Alternative Antibody Names | Anti-Neuropilin-1 antibodyAnti-Vascular Endothelial Cell Growth Factor 165 Receptor antibodyAnti-Cd Antigen Cd304 antibodyAnti-NRP1 antibodyAnti-NRP antibodyAnti-VEGF165R antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
